CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
HYMEDNA is developing highly sensitive biosensors for the early detection of cancer by identifying hypermethylated DNA in bodily fluids. This technology aims to provide a cost-effective and straightforward method for cancer screening, enhancing early diagnosis and treatment.
HYMEDNA prepares commercialization of very sensitive point-of-care biosensors for early-stage cancer detection based on the electrical detection of hypermethylated DNA (hmDNA) inside nanogaps.Only recently the awareness has risen that local hypermethylation of DNA provides a generic marker for a wide range of cancers. A robust, simple and cheap method for detecting hmDNA at low concentrations in blood, urine or faeces would be a major step forward in the early-stage detection of cancer.
Existing…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
